Skip to main content

Antihypertensive Therapy and Cancer Risk

Drug Safety volume 24, pages 727–739 (2001)Cite this article

Abstract

The aim of this article is to provide an overview of the available data linking antihypertensive drug therapy to cancer risk. In recent years, a number of mainly retrospective studies have reached different conclusions on the risk of cancer in patients with hypertension being treated with different antihypertensive drugs. At some point or another nearly all antihypertensive drugs have been suggested to increase the risk of cancer. Some studies have even found an association between hypertension itself and increased carcinogenesis. For calcium channel antagonists, β-blockers and α-blockers, the available evidence seems to favour a neutral effect on cancer development and death rate. For ACE inhibitors, the overall data suggest a similar neutral effect on cancer or, possibly, a small protective effect. Perhaps the strongest evidence in favour of a link, although probably weak, between cancer and antihypertensive drugs is with the diuretics. Until further solid data are available from prospective clinical trials, we suggest that the management of hypertension should continue according to current treatment guidelines with little fear of any substantial cancer risk.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I
Table II
Table III
Table IV

References

  1. Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose,lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertensionin the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998; 158(7): 741–751

    PubMed  CAS  Article  Google Scholar 

  2. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304 (6824): 405–12

    Google Scholar 

  3. Staessen J, Bulpitt C, Clement D, et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ 1989; 298(6687): 1552–6

    PubMed  CAS  Article  Google Scholar 

  4. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293(6555): 1145–51

    PubMed  CAS  Article  Google Scholar 

  5. Hamet P. Cancer and hypertension. An unresolved issue. Hypertension 1996; 28(3): 321–4

    PubMed  CAS  Article  Google Scholar 

  6. Ahmad S. Lymphoma and methyldopa therapy. J Am Geriatr Soc 1995; 43(8): 941–2

    PubMed  CAS  Google Scholar 

  7. Armstrong B, Stevens N, Doll R. Retrospective study of the association between use of rauwolfia derivatives and breast cancer in English women. Lancet 1974; II(7882): 672–5

    Article  Google Scholar 

  8. Bastiaens MT, Zwan NV, Verschueren GL, et al. Three cases of pemphigus vegetans: induction by enalapril - association with internal malignancy. Int J Dermatol 1994; 33(3): 168–71

    PubMed  CAS  Google Scholar 

  9. Broden G, Bengtsson L. Biliary carcinoma associated with methyldopa therapy. Acta Chir Scand Suppl 1980; 500: 7–12

    PubMed  CAS  Google Scholar 

  10. Finkle WD, McLaughlin JK, Rasgon SA, et al. Increased risk of renal cell cancer among women using diuretics in the United States. Cancer Causes Control 1993; 4(6): 555–8

    PubMed  CAS  Article  Google Scholar 

  11. Heath Jr CW, Lally CA, Calle EE, et al. Hypertension, diuretics, and antihypertensive medications as possible risk factors for renal cell cancer. Am J Epidemiol 1997; 145(7): 607–13

    PubMed  Article  Google Scholar 

  12. Heinonen OP, Shapiro S, Tuominen L, et al. Reserpine use in relation to breast cancer. Lancet 1974; II(7882): 675–7

    Article  Google Scholar 

  13. Larbre JP, Nicolas JF, Collet P, et al. Kaposi’s sarcoma in a patient with rheumatoid arthritis - possible responsibility of captopril in the development of lesions [see comments]. J Rheumatol 1991; 18(3): 476–7

    PubMed  CAS  Google Scholar 

  14. Pahor M, Guralnik JM, Salive ME, et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9(7): 695–9

    PubMed  CAS  Article  Google Scholar 

  15. Puppin Jr D, Rybojad M, de la Chapelle C, et al. Kaposi’s sarcoma associated with captopril. Lancet 1990; 336(8725): 1251–2

    PubMed  Article  Google Scholar 

  16. Dyer AR, Stamler J, Berkson DM, et al. High blood-pressure: a risk factor for cancer mortality? Lancet 1975; I(7915): 1051–6

    Article  Google Scholar 

  17. Raynor Jr WJ, Shekelle RB, Rossof AH, et al. High blood pressure and 17-year cancer mortality in the Western Electric Health Study. Am J Epidemiol 1981; 113(4): 371–7

    PubMed  Google Scholar 

  18. Buck C, Donner A. Cancer incidence in hypertensives. Cancer 1987; 59(7): 1386–90

    PubMed  CAS  Article  Google Scholar 

  19. Goldbourt U, Holtzman E, Yaari S, et al. Elevated systolic blood pressure as a predictor of long-term cancer mortality: analysis by site and histologic subtype in 10,000 middle-aged and elderly men. J Natl Cancer Inst 1986; 77(1): 63–70

    PubMed  CAS  Google Scholar 

  20. Khaw KT, Barrett-Connor E. Systolic blood pressure and cancer mortality in an elderly population. Am J Epidemiol 1984; 120(4): 550–8

    PubMed  CAS  Google Scholar 

  21. Svardsudd K, Tibblin G. Mortality and morbidity during 13.5 years’ follow-up in relation to blood pressure: the study of men born in 1913. Acta Med Scand 1979; 205(6): 483–92

    PubMed  CAS  Article  Google Scholar 

  22. Wannamethee G, Shaper AG. Blood pressure and cancer in middle-aged British men. Int J Epidemiol 1996; 25(1): 22–31

    PubMed  CAS  Article  Google Scholar 

  23. Taylor JO, Cornoni-Huntley J, Curb JD, et al. Blood pressure and mortality risk in the elderly. Am J Epidemiol 1991; 134(5): 489–501

    PubMed  CAS  Google Scholar 

  24. Weinmann S, Glass AG, Weiss NS, et al. Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer. Am J Epidemiol 1994; 140(9): 792–804

    PubMed  CAS  Google Scholar 

  25. Yano K, McGee D, Reed DM. The impact of elevated blood pressure upon 10-year mortality among Japanese men in Hawaii: the Honolulu Heart Program. J Chronic Dis 1983; 36(8): 569–79

    PubMed  CAS  Article  Google Scholar 

  26. Hole DJ, Hawthorne VM, Isles CG, et al. Incidence of and mortality from cancer in hypertensive patients. BMJ 1993; 306(6878): 609–11

    PubMed  CAS  Article  Google Scholar 

  27. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 62(2): 347–504

    PubMed  CAS  Google Scholar 

  28. Tremblay J, Hadrava V, Kruppa U, et al. Enhanced growth-dependent expression of TGF beta 1 and hsp70 genes in aortic smooth muscle cells from spontaneously hypertensive rats. Can J Physiol Pharmacol 1992; 70(4): 565–72

    PubMed  CAS  Article  Google Scholar 

  29. Hadrava V, Tremblay J, Hamet P. Abnormalities in growth characteristics of aortic smooth muscle cells in spontaneously hypertensive rats. Hypertension 1989; 13(6 Pt 1): 589–97

    PubMed  CAS  Article  Google Scholar 

  30. Paquet JL, Baudouin-Legros M, Marche P, et al. Enhanced proliferating activity of cultured smooth muscle cells from SHR. Am J Hypertens 1989; 2(2 Pt 1): 108–10

    PubMed  CAS  Google Scholar 

  31. Hamet P, deBlois D, Dam TV, et al. Apoptosis and vascular wall remodeling in hypertension. Can J Physiol Pharmacol 1996; 74(7): 850–61

    PubMed  CAS  Article  Google Scholar 

  32. Hamet P, Richard L, Dam TV, et al. Apoptosis in target organs of hypertension. Hypertension 1995; 26(4): 642–8

    PubMed  CAS  Article  Google Scholar 

  33. Hamet P. Proliferation and apoptosis of vascular smooth muscle in hypertension. Curr Opin Nephrol Hypertens 1995; 4(1):1–7

    PubMed  CAS  Article  Google Scholar 

  34. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26(4): 239–57

    PubMed  CAS  Article  Google Scholar 

  35. Norden A, Schersten B, Thulin T, et al. Hypertension related to DNA repair synthesis and carcinogen uptake. Lancet 1975; II(7944): 1094

    Article  Google Scholar 

  36. Pero RW, Bryngelsson C, Mitelman F, et al. High blood pressure related to carcinogen-induced unscheduled DNA synthesis, DNA carcinogen binding, and chromosomal aberrations in human lymphocytes. Proc Natl Acad Sci U S A 1976; 73(7): 2496–500

    PubMed  CAS  Article  Google Scholar 

  37. Ueda N, Kondo M. Chromosome aberrations induced by 7,12-dimethylbenz[a]-anthracene in bone marrow cells of spontaneously hypertensive rats (SHR) and control Wistar Kyoto(WKY) rats: time course and site specificity. J Natl Cancer Inst 1984; 73(2): 525–30

    PubMed  CAS  Google Scholar 

  38. Mehta RS, Gunnett CA, Harris SR, et al. High fish oil diet increases oxidative stress potential in mammary gland of spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1994; 21(11): 881–9

    PubMed  CAS  Article  Google Scholar 

  39. le Noble FAC, Staessen FRM, Hacking WJG, et al. Angiogenesis and hypertension. J Hypertens 1998; 16: 1563–72

    PubMed  Article  Google Scholar 

  40. Belgore F, Blann AD, Li-Saw-Hee FL, et al. Plasma levels of vascular endothelial growth factor and its soluble receptor Flt-1 in essential hypertension. Am J Cardiol 2001; 87(6): 805–7

    PubMed  CAS  Article  Google Scholar 

  41. Belgore F, Lip GYH, McCollum CN, et al. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor (sFlt-1) levels in coronary artery disease and peripheral artery disease. Blood Coagul Fibrinolysis 1999; 10: 536

    Article  Google Scholar 

  42. Hojo Y, Ikeda U, Zhu Y, et al. Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol 2000 Mar 15; 35(4): 968–73

    PubMed  CAS  Article  Google Scholar 

  43. McCredie M, Stewart JH. Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control 1992; 3(4): 323–31

    PubMed  CAS  Article  Google Scholar 

  44. Yu MC, Mack TM, Hanisch R, et al. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst 1986; 77(2): 351–6

    PubMed  CAS  Google Scholar 

  45. Kreiger N, Marrett LD, Dodds L, et al. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control 1993; 4(2): 101–10

    PubMed  CAS  Article  Google Scholar 

  46. Hiatt RA, Tolan K, Quesenberry Jr CP. Renal cell carcinoma and thiazide use: a historical, case-control study (California, USA). Cancer Causes Control 1994; 5(4): 319–25

    PubMed  CAS  Article  Google Scholar 

  47. Mellemgaard A, Niwa S, Mehl ES, et al. Risk factors for renal cell carcinoma in Denmark: role of medication and medical history. Int J Epidemiol 1994; 23(5): 923–30

    PubMed  CAS  Article  Google Scholar 

  48. Chow WH, McLaughlin JK, Mandel JS, et al. Risk of renal cell cancer in relation to diuretics, antihypertensive drugs, and hypertension. Cancer Epidemiol Biomarkers Prev 1995; 4(4): 327–31

    PubMed  CAS  Google Scholar 

  49. McLaughlin JK, Chow WH, Mandel JS, et al. International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int J Cancer 1995; 63(2): 216–21

    PubMed  CAS  Article  Google Scholar 

  50. Mellemgaard A, Moller H, Olsen JH. Diuretics may increase risk of renal cell carcinoma. Cancer Causes Control 1992; 3(4): 309–12

    PubMed  CAS  Article  Google Scholar 

  51. Prineas RJ, Folsom AR, Zhang ZM, et al. Nutrition and other risk factors for renal cell carcinoma in postmenopausal women. Epidemiology 1997; 8(1): 31–6

    PubMed  CAS  Article  Google Scholar 

  52. Grossman E, Messerli FH, Goldbourt U. Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol 1999; 83(7): 1090–3

    PubMed  CAS  Article  Google Scholar 

  53. Lindblad P, McLaughlin JK, Mellemgaard A, et al. Risk of kidney cancer in among patients using analgesics and diuretics: a population based cohort study. Int J Cancer 1993; 55: 5–9

    PubMed  CAS  Article  Google Scholar 

  54. Carlson JE, Kober L, Torp-Pedersen C, et al. Relation between dose of bendrofluazide, anihypertensive effect, and adverse biochemical effects. BMJ 1990; 300: 975–8

    Article  Google Scholar 

  55. Lijinsky W, Epstein SS. Nitrosamines as environmental carcinogens. Nature 1970; 225(227): 21–3

    PubMed  CAS  Article  Google Scholar 

  56. Gold B, Mirvish SS. N-Nitroso derivatives of hydrochlorothiazide, niridazole, and tolbutamide. Toxicol Appl Pharmacol 1977; 40(1): 131–6

    PubMed  CAS  Article  Google Scholar 

  57. Lijinsky W, Reuber MD. Pathologic effects of chronic administration of hydrochlorothiazide, with and without sodium nitrite, to F344 rats. Toxicol Ind Health 1987; 3(3): 413–22

    PubMed  CAS  Google Scholar 

  58. Loffing J, Loffing-Cueni D, Hegyi I, et al. Thiazide treatment of rats provokes apoptosis in distal tubule cells. Kidney Int 1996; 50(4): 1180–90

    PubMed  CAS  Article  Google Scholar 

  59. Wolf DC, Goldsworthy TL, Donner EM, et al. Estrogen treatment enhances hereditary renal tumor development in Eker rats. Carcinogenesis 1998; 19(11): 2043–7

    PubMed  CAS  Article  Google Scholar 

  60. Klungel OH, de Boer A, Paes AH, et al. Sex differences in antihypertensive drug use: determinants of the choice of medication for hypertension. J Hypertens 1998; 16(10): 1545–53

    PubMed  CAS  Article  Google Scholar 

  61. Verlander JW, Tran TM, Zhang L, et al. Estradiol enhances thiazide-sensitive NaCl cotransporter density in the apical plasma membrane of the distal convoluted tubule in ovariectomized rats. J Clin Invest 1998; 101(8): 1661–9

    PubMed  CAS  Article  Google Scholar 

  62. Sever PS, Dahlof B, Poulter NR, et al. Rationale, design, methods and baseline demography of participants of the Anglo Scandinavian Cardiac Outcomes Trial. Ascot Investigators. J Hypertens 2001; 19: 1139–47

    PubMed  CAS  Article  Google Scholar 

  63. Errea-Abad JM, Ara-Callizo JR, Aibar-Remon C. Drug-induced parkinsonism. Clinical aspects compared with Parkinson disease [Spanish]. Rev Neurol 1998; 27(155): 35–9

    PubMed  CAS  Google Scholar 

  64. Jonas M, Goldbourt U, Boyko V, et al. Nifedipine and cancer mortality: ten-year follow-up of 2607 patients after acute myocardial infarction. Cardiovasc Drugs Ther 1998; 12(2): 177–81

    PubMed  CAS  Article  Google Scholar 

  65. Sleight P. Calcium antagonists during and after myocardial infarction. Drugs 1996; 51(2): 216–25

    PubMed  CAS  Article  Google Scholar 

  66. Wagenknecht LE, Furberg CD, Hammon JW, et al. Surgical bleeding: unexpected effect of a calcium antagonist. BMJ 1995; 310(6982): 776–7

    PubMed  CAS  Article  Google Scholar 

  67. Maxwell CJ, Hogan DB, Ebly EM. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging [published erratum appears in CMAJ 1999 Nov 30; 161(11): 1396]. CMAJ 1999; 161(5): 501–6

    PubMed  CAS  Google Scholar 

  68. Jick H, Jick S, Derby LE, et al. Calcium-channel blockers and risk of cancer. Lancet 1997; 349(9051): 525–8

    PubMed  CAS  Article  Google Scholar 

  69. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348(9026): 493–7

    PubMed  CAS  Article  Google Scholar 

  70. Fitzpatrick AL, Daling JR, Furberg CD, et al. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997; 80(8): 1438–47

    PubMed  CAS  Article  Google Scholar 

  71. Braun S, Boyko V, Behar S, et al. Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. Benzafibrate Infarction Prevention (BIP) Study Research Group. J Am Coll Cardiol 1998; 31(4): 804–8

    PubMed  CAS  Article  Google Scholar 

  72. Hole DJ, Gillis CR, McCallum IR, et al. Cancer risk of hypertensive patients taking calcium antagonists. J Hypertens 1998; 16(1): 119–24

    PubMed  CAS  Article  Google Scholar 

  73. Meier CR, Derby LE, Jick SS, et al. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000; 160(3): 349–53

    PubMed  CAS  Article  Google Scholar 

  74. Sorensen HT, Olsen JH, Mellemkjaer L, et al. Cancer risk and mortality in users of calcium channel blockers. Acohort study. Cancer 2000; 89(1): 165–70

    PubMed  CAS  Article  Google Scholar 

  75. Stahl M, Bulpitt CJ, Palmer AJ, et al. Calcium channel blockers, ACE inhibitors, and the risk of cancer in hypertensive patients: a report from the Department of Health Hypertension Care Computing Project (DHCCP). J Hum Hypertens 2000; 14(5): 299–304

    PubMed  CAS  Article  Google Scholar 

  76. Rosenberg L, Rao RS, Palmer JR, et al. Calcium channel blockers and the risk of cancer. JAMA 1998; 279(13): 1000–4

    PubMed  CAS  Article  Google Scholar 

  77. Olsen JH, Toft Sorensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension 1997; 29(5): 1091–4

    PubMed  CAS  Article  Google Scholar 

  78. Trenkwalder P, Hendricks P, Hense HW. Treatment with calcium antagonists does not increase the risk of fatal or non-fatal cancer in an elderly mid-European population: results from STEPHYII. Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly. J Hypertens 1998; 16(8): 1113–6

    PubMed  CAS  Article  Google Scholar 

  79. Dong EW, Connelly JE, Borden SP, et al. A systematic review and meta-analysis of the incidence of cancer in randomized, controlled trials of verapamil. Pharmacotherapy 1997; 17(6): 1210–9

    PubMed  CAS  Google Scholar 

  80. Michels KB, Rosner BA, Walker AM, et al. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the nurses’ health study. Cancer 1998; 83(9): 2003–7

    PubMed  CAS  Article  Google Scholar 

  81. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350(9080): 757–64

    PubMed  CAS  Article  Google Scholar 

  82. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352(9123): 179–84

    PubMed  CAS  Article  Google Scholar 

  83. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327 (10): 685–91

  84. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145–53

    PubMed  CAS  Article  Google Scholar 

  85. Vogt B, Frey FJ. Inhibition of angiogenesis in Kaposi’s sarcoma by captopril. Lancet 1997; 349(9059): 1148

    PubMed  CAS  Article  Google Scholar 

  86. Volpert OV, Ward WF, Lingen MW, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996; 98(3): 671–9

    PubMed  CAS  Article  Google Scholar 

  87. Hii SI, Nicol DL, Gotley DC, et al. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998; 77(6): 880–3

    PubMed  CAS  Article  Google Scholar 

  88. Bouck N, Campbell S. Anti-cancer dividends from captopril and other inhibitors of angiogenesis. J Nephrol 1998; 11(1): 3–4

    PubMed  CAS  Google Scholar 

  89. Small Jr W, Molteni A, Kim YT, et al. Mechanism of captopril toxicity to a human mammary ductal carcinoma cell line in the presence of copper. Breast Cancer Res Treat 1999; 55(3): 223–9

    PubMed  CAS  Article  Google Scholar 

  90. Medical Research Council Working Party. Medical Research Council trial of treatment of mild hypertension: principle results. BMJ 1985; 291: 97–104

    Google Scholar 

  91. The IPPPSH Collaborative Group. Cardiovascular risk and risk factor in a randomised trial of treatment based on the betablocker oxprenolol: the international prospective primary prevention study in hypertension. J Hypertens 1985; 3: 379–92

    Google Scholar 

  92. Boston Collaborative Drug Surveillance Program. Reserpine and breast cancer: report from the Boston Collaborative Drug Surveillance Program. Lancet 1974; II (7882): 669–71

    Google Scholar 

  93. Curb JD, Hardy RJ, Labarthe DR, et al. Reserpine and breast cancer in the Hypertension Detection and Follow-Up Program. Hypertension 1982; 4(2): 307–11

    PubMed  CAS  Article  Google Scholar 

  94. Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 2000; 60(16): 4550–5

    PubMed  CAS  Google Scholar 

  95. Gago-Dominguez M, Yuan JM, Castelao JE, et al. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 1999; 81(3): 542–8

    PubMed  CAS  Article  Google Scholar 

  96. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999 Feb; 17(2): 151–83

    Google Scholar 

  97. Ramsay LE, Williams B, Johnston GD, et al. Guidelines for management of hypertension: report of the third working party of the British Hyppertension Society. J Human Hypertens 1999; 13: 569–92

    CAS  Article  Google Scholar 

Download references

Acknowledgments

We acknowledge the support of the City Hospital NHS Trust Research and Development programme for the Haemostasis, Thrombosis and Vascular Biology Unit.

Author information

Affiliations

  1. University Department of Medicine, City Hospital, Dudley Road, Birmingham, B18 7QH, England

    Dirk C. Felmeden &  Gregory Y.H. Lip

Authors
  1. Dirk C. Felmeden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory Y.H. Lip
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Felmeden, D.C., Lip, G.Y. Antihypertensive Therapy and Cancer Risk. Drug-Safety 24, 727–739 (2001). https://doi.org/10.2165/00002018-200124100-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200124100-00002

Keywords

  • Renal Cell Carcinoma
  • Antihypertensive Drug
  • Renal Cell Cancer
  • Calcium Channel Antagonist
  • Increase Cancer Risk